title: [Varicella vaccination in Germany. A provisional appraisal in the context of MMR vaccination].
abstract: In 2004, a general varicella immunization was introduced in Germany for infants from the age of 11 months, followed by the subsequent recommendation in 2009 of a second vaccine dose. The vaccination is carried out at the same time as the immunization against measles, mumps, and rubella (MMR). Results of the nationwide sentinel surveillance of varicella and herpes zoster implemented by the Varicella Working Group (Arbeitsgemeinschaft Varizellen, AGV) show that the defined goals for varicella immunization (reduction of varicella-related morbidity, complications and hospitalizations) have been reached within a few years owing to the advances in vaccine coverage. Although coverage rates for varicella have not yet reached the same levels as for MMR, varicella immunization seems to have benefited from the established MMR immunization schedule. Moreover, there is no evidence for an adverse effect on the use and acceptance of the MMR vaccine. Lessons learnt in measles epidemiology (such as trends in the incidence of the disease in adolescents and infants), as well as in the history of MMR recommendations, may be useful for the evaluation of future epidemiological changes with respect to varicella and herpes zoster. In view of a rapidly waning immunity against the varicella zoster virus after vaccination with one dose and the lifelong persistence of the virus, achieving a robust and sustainable immunity in the general population seems to be an ambitious goal. However, this accomplishment will be indispensable in preventing breakthrough infections and a shift of varicella to older ages and in avoiding an increase in herpes zoster incidence.
authors.affiliation: Abt. für Infektionsepidemiologie, Fachgebiet Impfprävention, Robert Koch-Institut, DGZ-Ring 1, 13086, Berlin, Deutschland. siedlera@rki.de
authors.forename: A
authors.initials: A
authors.lastname: Siedler
authors.forename: J
authors.initials: J
authors.lastname: Hecht
authors.forename: T
authors.initials: T
authors.lastname: Rieck
authors.forename: K
authors.initials: K
authors.lastname: Tolksdorf
authors.forename: H
authors.initials: H
authors.lastname: Hengel
mesh_terms: D000293:Adolescent; D002644:Chickenpox / Q000453:epidemiology* / Q000517:prevention & control*; D002648:Child; D002675:Child, Preschool; D060740:Disease Eradication / Q000379:methods*; D019353:Endemic Diseases / Q000517:prevention & control* / Q000706:statistics & numerical data*; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D032541:Mass Vaccination / Q000706:statistics & numerical data*; D022542:Measles-Mumps-Rubella Vaccine / Q000627:therapeutic use*; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D022542:Measles-Mumps-Rubella Vaccine